Clinical use of approved influenza antivirals: Therapy and prophylaxis

Michael G. Ison*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


Currently, there are two commonly used classes of antiviral agents approved for the prevention of and treatment for influenza: the M2 Inhibitors (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, laninamivir, peramivir and zanamivir). These agents have been proven to be safe and effective alone or in combination for the treatment of uncomplicated influenza in otherwise healthy individuals. Although there are few prospective, randomized studies of these antivirals for the treatment of pregnant women, hospitalized patients, and immunocompromised patients infected with seasonal, pandemic, or avian H5N1 influenza, these agents are widely used for these indications. This article reviews the pharmacokinetics and clinical data available relative to the use of commercially available antiviral agents for the prevention of and treatment for influenza.

Original languageEnglish (US)
Pages (from-to)7-13
Number of pages7
JournalInfluenza and other respiratory viruses
Issue number1 SUPPL.1
StatePublished - Jan 2013


  • Adamantanes
  • Antiviral agents
  • Influenza
  • M2 inhibitors
  • Neuraminidase inhibitors

ASJC Scopus subject areas

  • Epidemiology
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Clinical use of approved influenza antivirals: Therapy and prophylaxis'. Together they form a unique fingerprint.

Cite this